Concentrated exposure treatment of obsessive-compulsive disorder: The Bergen 4-Day OCD Treatment (B4DT)

Concentrated exposure treatment of obsessive-compulsive disorder: The Bergen 4-Day OCD Treatment (B4DT) - B4DT-HH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00030022

Enrollment

Registered

2022-08-15

Start date

2022-09-05

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F42

Interventions

Group 1: The B4DT is conducted on four consecutive days in a group of 3 to 6 patients by the same number of therapists. The first day in the group setting is dedicated to manualized psychoeducation a

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Diagnosed with obsessive-compulsive disorder (ICD-10: F 42) 18 to 75 years of age Willingness and consent to participate in the study (informed consent) Stable pharmacological treatment before treatment start

Exclusion criteria

Exclusion criteria: Acute suicidality Psychotic symptoms Substance dependence

Design outcomes

Primary

Measure	Time frame
The primary outcome parameter is the change in obsessive-compulsive symptomatology, assessed with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) from t0 to t1 and after the two follow-ups (t2 and t3). Response and remission will also be calculated using the Y-BOCS.	—

Secondary

Measure	Time frame
Secondary outcome parameters are the change in self-reported obsessive-compulsive symptoms and beliefs (OCI-R, OBQ-44), depression (PHQ-9) as well as self-esteem (RSES) and quality of life (WHOQoL-Bref) and experience avoidance/psychological flexibility (BEAQ) as well as the general level of functioning (GAF). In addition, at baseline (t0), motivation and previous therapy experiences are assessed. At t1 group processes (Group Questionnaire GQ-D) are assessed. From t1 to t3, patient satisfaction (ZUF-8), subjective evaluation of the intervention, and side effects (INEPS) will be measured. Questionnaires on exposures as well as on other therapy measures will be given at t2 and t3. At the four treatment days (at the beginning and end), patients will be asked questions to evaluate the treatment process (e.g., expectations of self-efficacy, treatment success, motivation, rating of distress, violation of expectancy). - At all measurement time points (t0, t1, t2, t3): Obsessive Compulsive Inventory- Revised (OCI-R), Obsessive-Beliefs-Questionnaire (OBQ-44) Patients health questionnaire – depression (PHQ-9), Rosenberg Self-Esteem Scale (RSES), WHO Quality of Life-BREF (WHOQoL-BREF), Global Assessment of Functioning (GAF), Brief Experiential Avoidance Questionnaire (BEAQ) - At t0: Questionnaire on motivation (including willingness to change, self-efficacy and treatment success expectations), Questionnaire on previous interventions - At t1: Group Questionnaire (GQ-D) - At t1, t2 and t3: Patient satisfaction questionnaire (ZUF-8), Subjective evaluation of the intervention, Side effects (INEPS) -At t2 and t3: Questionnaire on other exposures (e.g. type of exposure and number of exposures), Questionnaire on other interventions - During the treatment (at the start and end); Rating of the intervention (e.g., expectations of self-efficacy, treatment success, motivation, rating of distress, violation of expectancy)	—

Measure

Time frame

Secondary outcome parameters are the change in self-reported obsessive-compulsive symptoms and beliefs (OCI-R, OBQ-44), depression (PHQ-9) as well as self-esteem (RSES) and quality of life (WHOQoL-Bref) and experience avoidance/psychological flexibility (BEAQ) as well as the general level of functioning (GAF). In addition, at baseline (t0), motivation and previous therapy experiences are assessed. At t1 group processes (Group Questionnaire GQ-D) are assessed. From t1 to t3, patient satisfaction (ZUF-8), subjective evaluation of the intervention, and side effects (INEPS) will be measured. Questionnaires on exposures as well as on other therapy measures will be given at t2 and t3. At the four treatment days (at the beginning and end), patients will be asked questions to evaluate the treatment process (e.g., expectations of self-efficacy, treatment success, motivation, rating of distress, violation of expectancy). - At all measurement time points (t0, t1, t2, t3): Obsessive Compulsive Inventory- Revised (OCI-R), Obsessive-Beliefs-Questionnaire (OBQ-44) Patients health questionnaire – depression (PHQ-9), Rosenberg Self-Esteem Scale (RSES), WHO Quality of Life-BREF (WHOQoL-BREF), Global Assessment of Functioning (GAF), Brief Experiential Avoidance Questionnaire (BEAQ) - At t0: Questionnaire on motivation (including willingness to change, self-efficacy and treatment success expectations), Questionnaire on previous interventions - At t1: Group Questionnaire (GQ-D) - At t1, t2 and t3: Patient satisfaction questionnaire (ZUF-8), Subjective evaluation of the intervention, Side effects (INEPS) -At t2 and t3: Questionnaire on other exposures (e.g. type of exposure and number of exposures), Questionnaire on other interventions - During the treatment (at the start and end); Rating of the intervention (e.g., expectations of self-efficacy, treatment success, motivation, rating of distress, violation of expectancy)

—

Countries

Germany

Contacts

Public ContactJosefine Gehlenborg

Universitätsklinikum Hamburg-Eppendorf

j.gehlenborg@uke.de+49 40 7410-54227

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026